Rhythm Pharmaceuticals Inc Stock News

Equities research analysts forecast that Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) will report earnings of ($0.99) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Rhythm Pharmaceuticals earnings. The lowest EPS estimate is ($1.08) and the highest is ($0.90). Rhythm Pharmaceuticals reported earnings of ($0.79) per share during the same []

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)s share price was down 7% during mid-day trading on Tuesday . The company traded as low as $12.26 and last traded at $12.30. Approximately 9,488 shares were traded during trading, a decline of 97% from the average daily volume of 371,667 shares. The stock had previously closed at $13.23. A number []

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company''s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS) or Alström syndrome. The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2022. "The acceptance for filing of our supplemental application by the FDA marks an important step in our efforts to address the unmet needs and bring IMCIVREE to patients and families living with Bardet-Biedl syndrome and Alström syndrome," said Linda Shapiro, M.D., Ph.D., Chief Medical Officer of Rhythm Pharmaceuticals. "The FDA''s decision to grant Priority Review to the application aligns with our belief in the potential of IMCIVREE to deliver clinically meaningful and statistically significant reductions in body weight and hunger for patients with BBS and Alström syndrome while also substantially improving quality of life for these patients and their families." A Priority Review designation is granted by the FDA for the evaluation of drug applications that may offer significant improvements in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease.

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q3 2021 Results - Earnings Call Transcript

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare geneti

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare geneti

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger --   -- Updated result

-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from t

– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or bi

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic

Expanded access program may allow access for eligible patients in the United States who have no authorized treatment options Expanded access program may allow access for eligible patients in the Unite

-- Linda Shapiro Manning, M.D., Ph.D., promoted to Chief Medical Officer, effective Sept. 10 -- -- CMO Murray Stewart, M.D., to transition to Senior Medical Advisor -- BOSTON, Sept. 02, 2021 (GLOBE NE

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic